| RHEUMATO-DERMATOLOGY SYMPOSIUM |
|
| Year : 2019 | Volume
: 3
| Issue : 1 | Page : 41-46 |
|
|
Biologicals in the management of rheumatodermatologic conditions and beyond
CB Mithun, B Harikrishnan
Department of Clinical Immunology and Rheumatology, Amrita Institute of Medical Sciences, Kochi, Kerala, India
Correspondence Address:
C B Mithun
Amrita Institute of Medical Sciences, Kochi, Kerala
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/CDR.CDR_51_18
|
|
|
Biologicals are synthesized from living cells by biotechnology methods and typically include monoclonal antibodies and fusion proteins targeted against pathogenic cytokines, B or T cells, or its receptors. A biosimilar is a cheaper, manufactured product which is almost the same as biological. Appropriate patient selection is the key consideration before starting biologicals. Screening for tuberculosis is a must, except in case of rituximab. Tumor-necrosis-factor alpha inhibitors, interleukin (IL)-17A antagonists, anti-CD6 monoclonal antibodies (mAbs), and anti-IL-6 mAbs are discussed here for various indications.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
